Sophiris starts dosing patients in Phase III study of prostate drug

Canadian urology firm Sophiris Bio has dosed the first patient in a Phase III trial of PRX302 (topsalysin) for the treatment for lower urinary tract symptoms of benign prostatic hyperplasia (BPH or enlarged prostate).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news